| Literature DB >> 31936213 |
Ana Carolina Ruberte1,2, Sandra Ramos-Inza1,2, Carlos Aydillo1,2, Irene Talavera1,2, Ignacio Encío2,3, Daniel Plano1,2, Carmen Sanmartín1,2.
Abstract
Selenium compounds are pivotal in medicinal chemistry for their antitumoral and antioxidant properties. Forty seven acylselenoureas have been designed and synthesized following a fragment-based approach. Different scaffolds, including carbo- and hetero-cycles, along with mono- and bi-cyclic moieties, have been linked to the selenium containing skeleton. The dose- and time-dependent radical scavenging activity for all of the compounds were assessed using the in vitro 2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) assays. Some of them showed a greater radical scavenging capacity at low doses and shorter times than ascorbic acid. Therefore, four compounds were evaluated to test their protective effects against H2O2-induced oxidative stress. One derivative protected cells against H2O2-induced damage, increasing cell survival by up to 3.6-fold. Additionally, in vitro cytotoxic activity of all compounds was screened against several cancer cells. Eight compounds were selected to determine their half maximal inhibitory concentration (IC50) values towards breast and lung cancer cells, along with their selectivity indexes. The breast cancer cells turned out to be much more sensitive than the lung. Two compounds (5d and 10a) stood out with IC50 values between 4.2 μM and 8.0 μM towards MCF-7 and T47D cells, with selectivity indexes greater than 22.9. In addition, compound 10b exhibited dual antioxidant and cytotoxic activities. Although further evidence is needed, the acylselenourea scaffold could be a feasible frame to develop new dual agents.Entities:
Keywords: acylselenoureas; antioxidant; cytotoxicity; oxidative stress; radical scavenging; selenium
Year: 2020 PMID: 31936213 PMCID: PMC7023466 DOI: 10.3390/antiox9010055
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Figure 1Selenourea (A) and acylselenourea (B) derivatives with an antioxidant and/or anticancer activity.
Figure 2Structural design of the acylselenoureas presented in this work.
Scheme 1Synthesis of the acylselenourea derivatives. Reagent and conditions: (I) SOCl2, 150 °C, 1.5 h; (II) KSeCN, acetone (dry), room temperature, 1 h; (III) corresponding aniline, room temperature, 0.5–24 h.
Figure 32,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging activity of the novel compounds synthetized in this work. (A) Percentage of DPPH• scavenging after 0 min at the highest concentration tested (0.03 mg/mL); (B) percentage of DPPH• scavenging after 0 min at 0.003 mg/mL; (C) percentage of DPPH• scavenging at 0.03 mg/mL after 30 min for all of the 47 compounds. Significance: * p < 0.05 compared with ascorbic acid (Asc). The results obtained for lower concentrations and longer times are included in the Supplementary Material.
Figure 42,2′-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) radical scavenging activity of the novel acylselenourea compounds. (A) Percentage of ABTS+• scavenging after 0 min at the highest concentration tested (0.03 mg/mL); (B) percentage of ABTS+• scavenging after 0 min at 0.003 mg/mL; (C) percentage of ABTS+• scavenging at 0.03 mg/mL after 6 min of incubation for all the 47 compounds. Significance: * p < 0.05 compare with Asc and Trolox. The results obtained for longer times are included in the Supplementary Material.
Figure 5Antioxidant activity of hit compounds at 0.03 mg/mL (A) and 0.003 mg/mL (B) was evaluated using the H2O2-induced HT-29 cells oxidative damage model at 300 (blue), 250 (violet), and 200 µM (grey). The results are expressed as an increase fold of cell survival. Significance: * p < 0.05 compared with Asc.
Cytotoxic activity, expressed as average IC50 values (µM) and selectivity indexes (SI) calculated of derivatives 5d, 6a, 9e, 10a, 10b, 10c, 10d, and 10e.
| Compound | IC50 (µM) 1 | |||||
|---|---|---|---|---|---|---|
| Cell Lines | ||||||
| HTB-54 | H1299 | T47D | MCF-7 | 184B5 | SI 2 | |
|
| 14.6 ± 6.3 | 7.5 ± 0.2 | 6.1 ± 0.4 | 4.2 ± 0.2 | >100 | >23.7 |
|
| 26.1 ± 2.3 | 30.2 ± 7.2 | 7.8 ± 1.0 | 3.5 ± 0.6 | 52.2 ± 3.8 | 14.7 |
|
| >100 | 8.7 ± 1.4 | 7.1 ± 0.6 | 9.8 ± 0.9 | >100 | >10.2 |
|
| >100 | 11.2 ± 0.8 | 8.0 ± 1.0 | 4.4 ± 1.0 | >100 | >22.9 |
|
| 1.5 ± 1.8 | 5.9 ± 1.4 | 11.9 ± 1.0 | 7.3 ± 0.3 | >100 | >13.6 |
|
| 5.2 ± 4.0 | 7.3 ± 0.2 | 12.9 ± 1.5 | 8.5 ± 0.6 | 53.8 ± 10.5 | 6.3 |
|
| 23.4 ± 3.2 | 5.7 ± 0.1 | 11.8 ± 1.9 | 7.9 ± 0.7 | >100 | >12.7 |
|
| 2.9 ± 3.2 | 48.6 ± 0.9 | 17.4 ± 3.1 | 11.7 ± 1.5 | 73.1 ± 5.2 | 6.2 |
1 IC50: half maximal inhibitory concentration; 2 SI: Selectivity index was calculated as the ratio of the IC50 values determined for the non-malignant and the tumor cells (IC50 (184B5)/IC50 (MCF-7)).